TJ244R3 - (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment - Google Patents

(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Info

Publication number: TJ244R3
Authority: TJ; Tajikistan
Prior art keywords: oxathiolan; pyrimidin; hydroxymethyl; fluoro; amino
Prior art date: 1991-08-01

Application number

TJ94000128A

Other languages

English (en)

Inventor

Gervais Dionne

Original Assignee

Iaf Biochem Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-01

Filing date

1994-12-15

Publication date

1999-11-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TJ244(R3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-12-15 Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int

1994-12-15 Priority to TJ94000128A priority Critical patent/TJ244R3/xx

1999-11-24 Publication of TJ244R3 publication Critical patent/TJ244R3/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Analytical Chemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

TJ94000128A 1991-08-01 1994-12-15 (-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment TJ244R3 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
TJ94000128A TJ244R3 (en)	1991-08-01	1994-12-15	(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB919116601A GB9116601D0 (en)	1991-08-01	1991-08-01	1,3-oxathiolane nucleoside analogues
PCT/CA1992/000321 WO1993003027A1 (en)	1991-08-01	1992-07-24	1,3-oxathiolane nucleoside analogues
TJ94000128A TJ244R3 (en)	1991-08-01	1994-12-15	(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Publications (1)

Publication Number	Publication Date
TJ244R3 true TJ244R3 (en)	1999-11-24

Family

ID=10699340

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TJ94000128A TJ244R3 (en)	1991-08-01	1994-12-15	(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment

Country Status (40)

Country	Link
US (2)	US5538975A (de)
EP (2)	EP1155695B1 (de)
JP (1)	JP2960778B2 (de)
KR (1)	KR100242454B1 (de)
CN (5)	CN1034810C (de)
AP (1)	AP321A (de)
AT (2)	ATE227720T1 (de)
AU (1)	AU659668B2 (de)
BG (1)	BG61693B1 (de)
CA (2)	CA2114221C (de)
CZ (1)	CZ283765B6 (de)
DE (2)	DE69232845T2 (de)
DK (2)	DK0526253T3 (de)
EE (1)	EE03002B1 (de)
EG (1)	EG20193A (de)
ES (2)	ES2335968T3 (de)
FI (1)	FI940435L (de)
GB (1)	GB9116601D0 (de)
GE (1)	GEP20002094B (de)
HN (1)	HN1997000118A (de)
HU (2)	HUT70030A (de)
IL (1)	IL102616A (de)
MA (1)	MA22919A1 (de)
MD (1)	MD1434C2 (de)
MX (1)	MX9204474A (de)
NO (3)	NO300842B1 (de)
NZ (1)	NZ243637A (de)
OA (1)	OA09883A (de)
PH (1)	PH30983A (de)
PT (2)	PT526253E (de)
RS (1)	RS49993B (de)
RU (1)	RU2126405C1 (de)
SG (1)	SG68541A1 (de)
SK (1)	SK280131B6 (de)
TJ (1)	TJ244R3 (de)
TN (1)	TNSN92070A1 (de)
TW (2)	TWI232217B (de)
WO (1)	WO1993003027A1 (de)
YU (1)	YU49259B (de)
ZA (1)	ZA925668B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6903224B2 (en)	1988-04-11	2005-06-07	Biochem Pharma Inc.	Substituted 1,3-oxathiolanes
US6346627B1 (en)	1990-02-01	2002-02-12	Emory University	Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en)	1990-02-01	1999-06-22	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) *	1990-02-01	1994-01-04	Emory University	Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) *	1990-12-05	1999-07-20	Emory University	Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en)	1991-03-06	2004-11-02	Emory University	Therapeutic nucleosides
US5817667A (en) *	1991-04-17	1998-10-06	University Of Georgia Research Foudation	Compounds and methods for the treatment of cancer
GB9116601D0 (en) *	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) *	1992-12-24	1993-02-17	Iaf Biochem Int	Dideoxy nucleoside analogues
GB9311709D0 (en) *	1993-06-07	1993-07-21	Iaf Biochem Int	Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en)	1993-09-10	2002-08-29	Gilles Gosselin	2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en)	1993-09-10	1995-03-16	Emory University	Nucleosides with anti-hepatitis b virus activity
US5587362A (en) *	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
IL113432A (en)	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en)	1994-09-06	2000-07-16	Univ Georgia	Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en)	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en)	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) *	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) *	1995-03-31	1995-05-24	Wellcome Found	Preparation of nucleoside analogues
DK0831852T3 (da)	1995-06-07	2007-03-19	Univ Emory	Nukleosider med anti-hepatitis B-virusaktivitet
TW505653B (en) *	1996-02-26	2002-10-11	Meiji Seika Co	Triterpene derivatives possessing an effect of treating liver diseases and pharmacentical compositions containing the same
US5753789A (en) *	1996-07-26	1998-05-19	Yale University	Oligonucleotides containing L-nucleosides
CN1196701C (zh)	1997-03-19	2005-04-13	埃莫里大学	1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
EP0986375A2 (de)	1997-04-07	2000-03-22	Triangle Pharmaceuticals Inc.	Zusammensetzungen enthatend mkc-442 in kombination mit anderen antiviralen mitteln
PT1104415E (pt)	1998-08-12	2005-03-31	Univ Emory	Metodo de preparacao de nucleosidos de 1,3-oxatiolano
US6979561B1 (en)	1998-10-09	2005-12-27	Gilead Sciences, Inc.	Non-homogeneous systems for the resolution of enantiomeric mixtures
DE69923338T2 (de) *	1998-11-02	2006-04-06	Gilead Sciences, Inc., Foster City	Kombinationstherapie zur behandlung von hepatitis b infektionen
US6436948B1 (en)	2000-03-03	2002-08-20	University Of Georgia Research Foundation Inc.	Method for the treatment of psoriasis and genital warts
KR20080059679A (ko)	2000-03-29	2008-06-30	조지타운 유니버시티	델타형 간염 바이러스 감염의 치료방법
CA2308559C (en)	2000-05-16	2005-07-26	Brantford Chemicals Inc.	1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
KR20040002871A (ko) *	2001-03-01	2004-01-07	트라이앵글 파마슈티칼스 인코포레이티드	시스-ｆｔｃ의 다형 및 기타 결정형
AU2008202336B2 (en) *	2001-03-01	2011-11-10	Abbvie Inc.	Polymorphic and other crystalline forms of cis-FTC
CN1620295A (zh) *	2001-12-14	2005-05-25	法玛塞特有限公司	制备用于合成抗病毒核苷的中间体
WO2004064845A1 (en)	2003-01-14	2004-08-05	Gilead Sciences, Inc.	Compositions and methods for combination antiviral therapy
ITMI20030578A1 (it) *	2003-03-24	2004-09-25	Clariant Lsm Italia Spa	Processo ed intermedi per la preparazione di emtricitabina
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100360528C (zh) *	2005-08-31	2008-01-09	四川大学	4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) *	2005-12-30	2007-07-12	Ranbaxy Laboratories Limited	Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
NZ617066A (en) *	2008-12-23	2015-02-27	Gilead Pharmasset Llc	Nucleoside analogs
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
NZ593648A (en) *	2008-12-23	2013-09-27	Gilead Pharmasset Llc	Nucleoside phosphoramidates
US9683226B2 (en)	2009-04-03	2017-06-20	Medical Research Council	Mutants of activation-induced cytidine deaminase (AID) and methods of use
EP2377862A1 (de)	2010-03-29	2011-10-19	Esteve Química, S.A.	Verfahren zur Gewinnung von Emtricitabin
ES2644990T3 (es)	2010-03-31	2017-12-01	Gilead Pharmasset Llc	Síntesis estereoselectiva de principios activos que contienen fósforo
WO2013104361A1 (en)	2012-01-10	2013-07-18	C.C. Jensen A/S	Method and system for cleaning degraded oil
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5668674A (en) *	1979-11-08	1981-06-09	Shionogi & Co Ltd	5-fluorouracil derivative
DE2950317A1 (de) *	1979-12-14	1981-06-19	Agfa-Gevaert Ag, 5090 Leverkusen	Elektrothermographische vorrichtung
US5270315A (en) *	1988-04-11	1993-12-14	Biochem Pharma Inc.	4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) *	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) *	1989-02-08	1995-11-14	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
WO1994014802A1 (en) *	1989-02-08	1994-07-07	Biochem Pharma Inc.	Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) *	1990-02-01	1994-01-04	Emory University	Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) *	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
WO1992010496A1 (en) *	1990-12-05	1992-06-25	University Of Georgia Research Foundation, Inc.	ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5248776A (en) *	1990-12-05	1993-09-28	University Of Georgia Research Foundation, Inc.	Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100965A (en) *	1991-02-22	1999-12-31	Univ Emory	2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
EP1808434A3 (de) *	1991-03-06	2008-04-02	Emory University	Verwendung von 5-Fluoro-2'-deoxy-3'-thiacytidin zur Behandlung von Hepatitis B
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
WO1992018517A1 (en) *	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
GB9111902D0 (en) *	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
GB9116601D0 (en) *	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues

1991
- 1991-08-01 GB GB919116601A patent/GB9116601D0/en active Pending
1992
- 1992-07-20 NZ NZ243637A patent/NZ243637A/en unknown
- 1992-07-23 IL IL10261692A patent/IL102616A/en not_active IP Right Cessation
- 1992-07-24 RU RU94013464A patent/RU2126405C1/ru active
- 1992-07-24 CA CA002114221A patent/CA2114221C/en not_active Expired - Lifetime
- 1992-07-24 AU AU23408/92A patent/AU659668B2/en not_active Expired
- 1992-07-24 FI FI940435A patent/FI940435L/fi not_active Application Discontinuation
- 1992-07-24 KR KR1019940700260A patent/KR100242454B1/ko not_active Expired - Lifetime
- 1992-07-24 SK SK104-94A patent/SK280131B6/sk not_active IP Right Cessation
- 1992-07-24 JP JP5503131A patent/JP2960778B2/ja not_active Expired - Lifetime
- 1992-07-24 GE GEAP19922643A patent/GEP20002094B/en unknown
- 1992-07-24 WO PCT/CA1992/000321 patent/WO1993003027A1/en not_active Ceased
- 1992-07-24 CA CA2682254A patent/CA2682254C/en not_active Expired - Lifetime
- 1992-07-24 MD MD95-0114A patent/MD1434C2/ro unknown
- 1992-07-24 US US08/190,203 patent/US5538975A/en not_active Expired - Fee Related
- 1992-07-24 HU HU9400285A patent/HUT70030A/hu unknown
- 1992-07-24 CZ CZ94203A patent/CZ283765B6/cs not_active IP Right Cessation
- 1992-07-28 ZA ZA925668A patent/ZA925668B/xx unknown
- 1992-07-29 PH PH44737A patent/PH30983A/en unknown
- 1992-07-29 MA MA22897A patent/MA22919A1/fr unknown
- 1992-07-30 EG EG42992A patent/EG20193A/xx active
- 1992-07-31 TW TW088109613A patent/TWI232217B/zh not_active IP Right Cessation
- 1992-07-31 TN TNTNSN92070A patent/TNSN92070A1/fr unknown
- 1992-07-31 MX MX9204474A patent/MX9204474A/es active IP Right Grant
- 1992-07-31 TW TW081106093A patent/TW366347B/zh not_active IP Right Cessation
- 1992-07-31 YU YU74992A patent/YU49259B/sh unknown
- 1992-07-31 AP APAP/P/1992/000414A patent/AP321A/en active
- 1992-07-31 RS YUP-723/03A patent/RS49993B/sr unknown
- 1992-08-01 CN CN92108995A patent/CN1034810C/zh not_active Expired - Lifetime
- 1992-08-01 CN CNA2006100999092A patent/CN101074228A/zh active Pending
- 1992-08-01 CN CNA2006100999088A patent/CN101066970A/zh active Pending
- 1992-08-03 DK DK92307051T patent/DK0526253T3/da active
- 1992-08-03 AT AT92307051T patent/ATE227720T1/de active
- 1992-08-03 EP EP01119636A patent/EP1155695B1/de not_active Expired - Lifetime
- 1992-08-03 AT AT01119636T patent/ATE448787T1/de active
- 1992-08-03 DK DK01119636.7T patent/DK1155695T3/da active
- 1992-08-03 DE DE69232845T patent/DE69232845T2/de not_active Expired - Lifetime
- 1992-08-03 SG SG1996001043A patent/SG68541A1/en unknown
- 1992-08-03 PT PT92307051T patent/PT526253E/pt unknown
- 1992-08-03 DE DE69233776T patent/DE69233776D1/de not_active Expired - Lifetime
- 1992-08-03 EP EP92307051A patent/EP0526253B1/de not_active Expired - Lifetime
- 1992-08-03 ES ES01119636T patent/ES2335968T3/es not_active Expired - Lifetime
- 1992-08-03 PT PT01119636T patent/PT1155695E/pt unknown
- 1992-08-03 ES ES92307051T patent/ES2186667T3/es not_active Expired - Lifetime
1994
- 1994-01-31 NO NO940322A patent/NO300842B1/no not_active IP Right Cessation
- 1994-02-01 OA OA60465A patent/OA09883A/en unknown
- 1994-02-28 BG BG98616A patent/BG61693B1/bg unknown
- 1994-10-20 EE EE9400261A patent/EE03002B1/xx not_active IP Right Cessation
- 1994-12-15 TJ TJ94000128A patent/TJ244R3/xx unknown
1995
- 1995-06-07 US US08/487,452 patent/US5618820A/en not_active Expired - Fee Related
- 1995-06-30 HU HU95P/P00707P patent/HU211333A9/hu unknown
- 1995-11-03 CN CN95118741A patent/CN1074924C/zh not_active Expired - Lifetime
1997
- 1997-08-18 HN HN1997000118A patent/HN1997000118A/es unknown
2000
- 2000-05-26 CN CNB001179012A patent/CN100542535C/zh not_active Expired - Lifetime
2005
- 2005-08-19 NO NO2005017C patent/NO2005017I2/no not_active Application Discontinuation
2008
- 2008-06-12 NO NO2008009C patent/NO2008009I1/no unknown

Also Published As

Publication number	Publication date
SG68541A1 (en)	1999-11-16
ES2186667T3 (es)	2003-05-16
YU49259B (sh)	2004-12-31
CN101066970A (zh)	2007-11-07
FI940435A0 (fi)	1994-01-28
CN1074924C (zh)	2001-11-21
ES2335968T3 (es)	2010-04-07
US5538975A (en)	1996-07-23
AP321A (en)	1994-02-28
DK1155695T3 (da)	2010-04-06
FI940435A7 (fi)	1994-01-28
HK1038189A1 (en)	2002-03-08
SK280131B6 (sk)	1999-08-06
CN1034810C (zh)	1997-05-07
KR100242454B1 (ko)	2000-03-02
CA2682254A1 (en)	1993-02-18
NO940322D0 (no)	1994-01-31
YU74992A (sh)	1995-12-04
EP0526253B1 (de)	2002-11-13
EP0526253A1 (de)	1993-02-03
TWI232217B (en)	2005-05-11
MA22919A1 (fr)	1993-04-01
GEP20002094B (en)	2000-05-10
GB9116601D0 (en)	1991-09-18
HUT70030A (en)	1995-09-28
IL102616A0 (en)	1993-01-14
DE69232845T2 (de)	2003-04-24
WO1993003027A1 (en)	1993-02-18
NO2005017I2 (no)	2007-10-01
DK0526253T3 (da)	2003-03-17
ATE448787T1 (de)	2009-12-15
TNSN92070A1 (fr)	1993-06-08
PT526253E (pt)	2003-03-31
NO2008009I1 (no)	2008-06-30
CA2114221C (en)	2009-12-22
HU9400285D0 (en)	1994-05-30
MD950114A (en)	1996-06-28
CN1070191A (zh)	1993-03-24
CZ283765B6 (cs)	1998-06-17
EP1155695A1 (de)	2001-11-21
DE69233776D1 (de)	2009-12-31
JPH07500317A (ja)	1995-01-12
ZA925668B (en)	1993-04-28
CN1302612A (zh)	2001-07-11
YU72303A (sh)	2006-05-25
DE69232845D1 (de)	2002-12-19
HK1008672A1 (en)	1999-05-14
MD1434B2 (en)	2000-03-31
HU211333A9 (en)	1995-11-28
EE03002B1 (et)	1997-06-16
US5618820A (en)	1997-04-08
EG20193A (en)	1997-10-30
BG98616A (bg)	1995-03-31
CA2682254C (en)	2012-02-21
TW366347B (en)	1999-08-11
NO2005017I1 (no)	2005-09-05
CN101074228A (zh)	2007-11-21
IL102616A (en)	1996-10-31
AU659668B2 (en)	1995-05-25
PH30983A (en)	1997-12-23
MD1434C2 (ro)	2000-12-31
NZ243637A (en)	1995-03-28
NO940322L (no)	1994-03-21
OA09883A (en)	1994-09-15
RS49993B (sr)	2008-09-29
EP1155695B1 (de)	2009-11-18
CZ20394A3 (en)	1994-07-13
CN100542535C (zh)	2009-09-23
CA2114221A1 (en)	1993-02-18
MX9204474A (es)	1993-12-01
ATE227720T1 (de)	2002-11-15
JP2960778B2 (ja)	1999-10-12
RU2126405C1 (ru)	1999-02-20
FI940435L (fi)	1994-01-28
AP9200414A0 (en)	1992-07-31
CN1132073A (zh)	1996-10-02
NO300842B1 (no)	1997-08-04
HN1997000118A (es)	1999-11-12
SK10494A3 (en)	1994-12-07
BG61693B1 (bg)	1998-03-31
PT1155695E (pt)	2010-02-02
AU2340892A (en)	1993-03-02

Publication	Publication Date	Title
TJ244R3 (en)	1999-11-24	(-)-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(111)-pyrimidin-2-one mixture of its enantiomers method of its preparation method of treatment
NZ238017A (en)	1994-06-27	(-)-cis-4-amino-1 -(2-hydroxymethyl -1,3-oxathiolan-5-yl) -(1h)- pyrimidin-2-one, preparation and pharmaceutical compositions
NO2008010I1 (no)	2008-07-07	Kombinasjon av efavirenz, emtricitabin og tenofovirdisoproks: 1 eller salter derav
CA2311988A1 (en)	1992-12-04	Crystalline oxathiolane derivatives
DE69400256D1 (de)	1996-07-25	Verfahren zur Herstellung von mit Carbonat angereicherten Hydroxyapatit Zusammensetzungen
PL295811A2 (en)	1993-05-04	Method of obtaining 1,2-dihydro-2-ketopyridines
PL295673A2 (en)	1993-05-17	Method of obtaining novel derivatives of 1,4-benzodioxane
MA20084A1 (fr)	1984-12-31	Derives de la furo-(3,4-c)-pyridine leur preparation et compositions therapeutiques contenant ces derives.
FI913957A7 (fi)	1992-02-24	6,7-dihydro-3-fenyyli-1,2-bentsisoksatsol-4(5H)-oneja ja -oleja, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä
HUT48216A (en)	1989-05-29	Insecticidal, nematocidal, coccidiostatic compositions comprising n-phenylpyrazole derivatives and process for producing the active ingredients
BR9405206A (pt)	1995-08-01	Composto,composição para fumar,composição apropriada para consumo humano,processo para a produção de compostos,e processo para aromatizar tabaco
MA22154A1 (fr)	1991-12-31	Methode de preparation de derives de furo (3,4-c) pyridine sous forme non- racemique
IL111580A (en)	1999-10-28	Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
HUT54358A (en)	1991-02-28	Process for producing substituted 1,3,5-triazinetrione derivatives and medical compositions comprising such compounds as active ingredient
HUT44694A (en)	1988-04-28	Process for producing benzthiazinone derivatives, and fungicide compositions containing them as active components
GB9221234D0 (en)	1992-11-25	Stemmed flower-like decorating
HUT61878A (en)	1993-03-29	Nematocidal compositions comprising pyrimidine derivatives as active ingredient and process for producing the active ingredient
DE69225740D1 (de)	1998-07-09	Herstellung von L-Fucose-Dehydrogenase
AU647444B2 (en)	1994-03-24	Oxipurinol salt composition for oral administration for treating hyperurecemia
FI954183A0 (fi)	1995-09-06	Menetelmä valmistaa cis-4-amino-1-(2-hydroksimetyyli-1,3-oksatiolan-5-yyli)-(1H)-pyrimidin-2-onin (-)enantiomeeriä käytettäväksi virustenvastaisena aineena
PL288367A1 (en)	1992-07-13	Method of obtaining 1,3-dichloropropanol
HU896703D0 (en)	1990-02-28	Process for the preparation of composition for treating cardiac arrhytmia
IT8948600A0 (it)	1989-11-24	Composizione per la profilassi anticarie dello smalto umano
GB9219155D0 (en)	1992-10-28	A composition for the treatment of game birds,particularly grouse
BG95403A (en)	1995-04-28	Method for the preparation of medicament having antihypertension effect